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INTRODUCTION
The measurement process is an inherent component of scientific research in any of its disciplines. This allows defining dimensions and generating classifications, thereby facilitating description and communication of the results, which is a daily responsibility for clinicians and researchers (Streiner & Geoffrey, 2003) .
We continually estimate the quality of scientific articles for which instruments have been developed, to improve research reading and communication. Specifically, these instruments should allow the user to carefully analyse the results of healthcare research, and determine potential bias in the execution of these studies (Hirst & Altman, 2012; Stevens et al., 2014) . However, within the range of existing tools this objective appears to be quite different and, rather than assessing methodological quality (MQ), is geared toward improving the quality of reporting results (scoring systems or "checklists", e.g. CONSORT, STARD, STROBE, QUORUM and TREND (Hirst & Altman; Manterola et al.) .
The construct of MQ is multidimensional (Manterola et al., 2006) . Although there is no globally accepted version of its components (Armijo-Olivo et al., 2013) , it can be interpreted as a complex and multidimensional construct, that may include items and domains, such as, type of design, sample size, methodology, analysis quality and reporting quality. The above can be represented as a geometric figure of as many sides as there are domains incorporated into the construct (Fig. 1 ).
The MQ assessment is an essential step in increasing internal and external validity in research, which would influence the quality of articles published in journals (Manterola et al., 2006) . Instruments such as QUADAS, AMSTAR and others (Shea et al., 2007; Mokkink et al., 2009; Manterola et al., 2013) , have been used for these purposes.
Although, there are at least 26 validated instruments for measuring the MQ of randomised clinical trials (ArmijoOlivo et al.) , there is no single tool to determine MQ in prognosis studies (PS). There is only a proposal to evaluate PS quality in systematic reviews (SR) (Hayden et al., 2006) , a fact that hinders the development of SR in the clinical research scenario.
The recently created MInCir scale (Methodology for Research in Surgery) to assess MQ in PS, is composed of 10 items grouped into 4 domains (Table I) . Instructions for its use, have been published with the aim of providing a guideline for its standardized application (Manterola et al., 2015) .
The aim of this study was to validate a scale to determine the MQ in PS.
MATERIAL AND METHOD
Study design: Scale validation study (Streiner & Geoffrey 
. Characterisation of the populatio n under study
The spectrum of the study subjects i s representative of the population for which it is desired to extrapolate t he results.
3 The spectrum of the study subjects is partially representative of the population for which it is desired to ext rapolate the results 1
Item 5. Characteristics of the reference standard applied
The same reference st andard is applied to all the patients independent of the results 3 The reference standard is applied partially or di fferent ially 2 There is no report of the standard of reference used 1 Item 6. Characteristics of the diagnostic test under study The diagnosti c test under study is described with sufficient detail to allow the replication.
3 The diagnosti c test under study is onl y partially described. Reuters, 2018) . A simple random sample of 140 articles was performed applying Streiner feasibility criteria, there should be at least 10 articles per item (Streiner & Geoffrey) . Of the random sample (140), 21 did not allow for the evaluation of instrument items due to problems with the quality of previously reported results. Two researchers (DZ and CM) independently applied the instrument in a sample of 119 articles, settling disagreements by consensus, thereby obtaining two independent scores and one consensual score.
Criterion and construct validity: Using the consensus score, criterion validity was determined by contrasting MQ scores with the levels of evidence of the Oxford Centre for Evidence-Based Medicine (CEBM, 2009). Construct validity was determined via extreme group analysis by dichotomising the IF of journals in which the aforementioned studies were published.
Interobserver reliability: Using the two independent scores, the degree of agreement between evaluators was determined.
Statistical analysis: Measures of central tendency and dispersion were used. The cut-off point was determined using ROC curve. Criterion validity was determined using onefactor ANOVA and Duncan test. Construct validity was determined applying T-Test, and interobserver reliabilityby applying an intraclass correlation coefficient. Analyses were performed using STATA 10/SE (Stata Corp., TX, USA).
RESULTS
For sensitivity and specificity analysis, area under ROC curve was 82.6 % (Fig. 2) . The best cut-off point was 33 to define the MQ construct and differentiate a good and poor MQ in PS (Table II) .
Criterion validity was determined comparing the MQ with the levels of evidence. The levels of evidence of the sample of articles were 1b (21 articles, 17.6 %), 2b (15 articles, 12.6 %) and 4 (83 articles, 69.8 %), which had mean MQ scores of 45.3±3.0, 40.8±2.8 and 27.3±2.5, respectively (p<0.0001), demonstrating the criterion validity of the scale.
Articles with high and low IF obtained mean MQ scores of 38.8±8.0 and 27.6±7.6, respectively (p<0.0001); criterion validity was checked in this way. Intraclass correlation coefficient for interobserver reliability was 0.91 (p=0.1082). In 52.9 % of the sample MQ was good. A description of the distribution of the total scores disaggregated by domain is presented in Table III . 
DISCUSSION
To determine instrument´s psychometric properties, a number of working strategies are necessary (Rojahn et al., 2011) . Therefore, the aim was to provide a useful tool to determine MQ of PS, because current instruments are scarce and their quality is questionable (Hayden et al., 2006; Armijo-Olivo et al.) .
We identified items and domains to define the construct of MQ in PS by generating a scale and assessing its performance in a sample of articles from different biomedical journals. Table III . Distribution of total score by domain of the scale of MQ in PS.
SD : Standard Deviation the levels of evidence are intended to value only the design of the studies (Manterola et al., 2013) , which is only one dimension evaluated when using this MQ construct. However, even if the level of evidence is an imperfect standard for MQ, it is useful to clearly distinguish prognosis scenarios (CEBM).
On the other hand, construct validity of extreme groups, is based on the IF of the journals that published the articles used in the analysis. The criterion seems reasonable, given the reported correlation between the IF for medical journals and the MQ of each article, as perceived by clinicians and biomedical researchers (Saha et al., 2003; Manterola et al., 2005a) . However, there is evidence of the controversial nature of using the IF as an indicator of MQ (Manterola et al., 2006) , since high-IF journals publish studies of low MQ (Gluud et al., 2005) . There is also information that dismisses the IF as an adequate measure to assess MQ (Favaloro, 2008) . The use of articles in different languages (English and Spanish) could be another source of bias to the limitations already mentioned with respect to the IF.
The high interobserver reliability could possibly be the result of the examiners' common views of the MQ construct and the interpretation of the scale under discussion. Hence the importance of calibrating observers to obtain reproducible results (Manterola et al., 2015) .
The scale, allows us not only to analyse an article based on a question of clinical use, but also to conduct bibliometric studies as in therapy scenarios (Manterola et al., 2006) . SR and meta-analyses of information can also be carried out by weighting the available evidence (Manterola et al., 2009) . This instrument therefore, represents a critical contribution to clinical research.
There is another tool for assessing MQ in PS (Quality in Prognosis Studies (QUIPS), which has recently been updated (Hayden et al., 2013) . This tool evaluates the quality of PS in SR. However, the approach is different in that it focuses on identifying research biases. It also presents differences in its development (Hayden et al., 2006 (Hayden et al., , 2008 (Hayden et al., , 2013 , which relate to the continuous refinement of the instrument by experts who recommend using it to evaluate bias in its six domains (Hayden et al., 2006 (Hayden et al., , 2008 (Hayden et al., , 2013 ).
This new scale will allow determining the MQ in PS, facilitating the work of readers, authors, reviewers and editors of biomedical journals. At the same time, it can be used to conduct bibliometric studies, and for weighting the quality of evidence through meta-analyses of information obtained from SR in prognosis scenarios, with primary studies of different types of designs.
Notwithstanding the above, the methods of this type of studies are not clearly defined. The scale uses specific items; the decision to classify the articles into three categories based on the IF distribution of WoS database journals; the cut-off points to discriminate the MQ dichotomously as good and bad; the choice to use the cutoff point 33 (based in the best under curve area (82.6 %) and correct classification (75.6 %), in addition to having good sensitivity (80.0 %), positive predictive value (82.6 %), positive likelihood ratio (3.01) and odds ratio (12.2).
Our purpose is to continue developing this scale and publish new information. We believe that the next steps should include confirming the psychometric properties of the scale in different specialties and disciplines, analyzing the correlation with QUIPS, and performing bibliometric studies and SR with PS. Thus, we believe that this scale can be used to define the MQ in PS, but we do not want it to become a static instrument.
In conclusion, we can point out that a scale to measure the MQ in PS was validated. RESUMEN: El objetivo de este estudio fue validar una escala para determinar calidad metodológica (CM) de estudios de pronóstico (EP). Se realizó un estudio de validación de escalas. La escala, compuesta por 10 ítems y 4 dominios; se aplicó a 119 artículos de 13 revistas, de factores de impacto alto, medio y bajo; por dos investigadores independientes. La validez del criterio se determinó al contrastar las puntuaciones de CM de cada artículo con los niveles de evidencia del Centro de Medicina Basada en la Evidencia de Oxford de la revista en la cual fueron publicados. Se estimó la validez de constructo de grupos extremos (factores de impacto alto y bajo). Se utilizó el coeficiente de correlación intraclase para determinar la confiabilidad interobservador, y el punto de corte se calculó construyendo curvas ROC. El mejor punto de corte fue 33 puntos (área bajo la curva de 82,6 %). La validez de criterio y de constructo fueron estadísticamente significativas (p<0,001). La confiabilidad interobservador fue 0,91. Se validó una escala para medir CM en EP.
PALABRAS CLAVE: Calidad metodológica; Pronós-tico; Estudios de validación de escalas; Medición; Medicina basada en evidencia.
